MedTrace Logo

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

NCT03150862 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-02-04

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma.

Conditions

Interventions

DRUG

Pamiparib

Administered as specified in the treatment arm

DRUG

TMZ

Administered as specified in the treatment arm

RADIATION

Radiation

Up to 60 Gy (total) over 6 - 7 weeks

Sponsors & Collaborators

  • BeiGene USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-24
Primary Completion
2021-03-17
Completion
2021-03-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03150862 on ClinicalTrials.gov